HTT and Huntington disease: Considering dominant inheritance in HD (6), the known disease-causing mutation (1), and an essential role for HTT in development (7–9), selective inactivation of mutant HTT through CRISPR/Cas9 genome editing may yield robust therapeutic benefits.